Elevation Oncology is a New York-based biopharmaceutical company that researches and develops precision therapies for the treatment of cancer.
Business Model:
Revenue: $0
Employees: 11-50
Address: 888 7th Avenue
City: New York
State: NY
Zip: 10106
Country: US
Elevation Oncology is a New York-based biopharmaceutical company that researches and develops precision therapies for the treatment of cancer.
Contact Phone:
+17163711125
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
6/24/2021
IPO Valuation:
$365M
Ticker Symbol:
ELEV
IPO Price:
$16/share
Amount Raised:
$100M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2020 | Series A | 5 | $32.5M |
Aisling Capital Vertex Ventures HC Qiming Venture Partners USA Driehaus Capital Management BVF Partners Aisling Capital |
7/2022 | Post-IPO Debt | 1 | $50M |
K2 HealthVentures K2 HealthVentures |
6/2021 | IPO | - | 7/2017 | Equity | $5.5M | 11/2020 | Series B | 11 | $65M |
Cormorant Asset Management venBio Partners Qiming Venture Partners USA Janus Henderson Investors Aisling Capital Driehaus Capital Management Samsara BioCapital BVF Partners Vivo Capital Cormorant Asset Management venBio Partners Boxer Capital Vertex Ventures HC Cormorant Asset Management venBio Partners Qiming Venture Partners USA Janus Henderson Investors Aisling Capital Driehaus Capital Management Samsara BioCapital BVF Partners Vivo Capital Cormorant Asset Management venBio Partners |
6/2021 | IPO | - |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|